SCHEMBL4392964

SCHEMBL4392964

COC(=O)c1cn(Cc2ccc(OC)cc2OC)c2nc(N3C[C@H](O)C[C@H]3CO)c(F)cc2c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 2/20 0.36
CD274 Q9NZQ7 2/20 0.36
LMNA P02545 1/20 0.36
CYP2C9 P11712 1/20 0.36
ATP6V1B2 P21281 1/20 0.36
TBXA2R P21731 1/20 0.36
EDNRA P25101 1/20 0.36
TARBP2 Q15633 1/20 0.36
DPP4 P27487 2/20 0.36
BTK Q06187 1/20 0.35
PPARG P37231 1/20 0.35
TP53 P04637 2/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TOP1 P11387 1/20 0.34
EGLN1 Q9GZT9 2/20 0.34
TACR1 P25103 1/20 0.34
MAP4K2 Q12851 1/20 0.33
STK4 Q13043 1/20 0.33
MAP4K1 Q92918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4399296 0.93 LMNA (0.43) PDCD1CD274LMNACYP2C9ATP6V1B2
SCHEMBL2091973 0.78 GNRHR (0.40) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL2095977 0.77 DPP4 (0.43) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL4541886 0.76 LMNA (0.43) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL2093477 0.76 LMNA (0.46) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL2095363 0.76 LMNA (0.46) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL2093865 0.75 LMNA (0.55) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL2093593 0.75 LMNA (0.55) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL2092595 0.75 GNRHR (0.38) TP53MAPT
SCHEMBL1020511 0.75 KMT2A (0.49) LMNACYP2C9ATP6V1B2TBXA2REDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632946-B2 Naphthyridine-based antibacterial compositions ABBOTT LABORATORIES (US) 2009-12-15 US disclosed
US-20070088040-A1 Antibacterial compounds ABBVIE INC. 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088040-A1 Antibacterial compounds MRPL21, FDPS, PGLS PDCD1 4167/4885CD274 4736/4885LMNA 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.